Physical and chemical properties of radionuclide therapy

Seminars in Radiation Oncology

Volumn 10, Issue 2, 2000, Pages 115-122

  Wessels, Barry W ^a,b   Meares, Claude F ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASTATINE 211; BISMUTH; COPPER 67; GOLD 198; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FRAGMENT; IODINE 131; LUTETIUM; MONOCLONAL ANTIBODY; PALLADIUM; PHOSPHORUS 32; RADIOISOTOPE; RHENIUM 186; SAMARIUM 153; SCANDIUM; YTTRIUM 90;

CANCER INHIBITION; CELL SURVIVAL; DOSIMETRY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG STABILITY; DRUG TARGETING; GAMMA RADIATION; HUMAN; ISOTOPE LABELING; PRIORITY JOURNAL; RADIOISOTOPE DECAY; RADIOISOTOPE THERAPY; REVIEW; TUMOR LOCALIZATION;

EID: 0034086254     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-4296(00)80048-X     Document Type: Article

References (56)

1. Leibel SA Kutcher GJ Mohan R Three-dimensional conformal radiation therapy at the Memorial Sloan-Kettering Cancer Center Semin Radiat Oncol 3 1992 274 289
2. Meeks SL Buatti JM Bova FJ Treatment planning optimization for linear accelerator radiosurgery Int J Radiat Oncol Biol Phys 41 1998 183 197
3. Shaw EG Radiotherapeutic management of multiple brain metastases: “3000 in 10” Whole brain radiation is no longer a “no brainer” Int J Radiat Oncol Biol Phys 45 1999 253 254
4. Hosain F Hosain P Therapy in Nuclear Medicine 1978 Grune & Stratton New York, NY
5. Wessels BW Rogus RD Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies Med Phys 11 1984 638 645
6. Jungerman JA Yu K-HP Zanelli CI Radiation absorbed dose estimates at the cellular level for some electron-emitting radionuclides for radioimmunotherapy Int J Appl Radiat Isot 35 1984 883 888
7. Humm JL Dosimetric aspects of radiolabeled antibodies for tumor therapy J Nucl Med 27 1986 1490 1497
8. Yorke ED Wessels BW Bradley EW Absorbed dose averages and dose heterogeneities in radioimmunotherapy Antib Immunoconj Radiopharmaceut 4 1991 623 629
9. Wessels BW Buchsbaum D Dosimetry of radiolabeled antibodies Smith AR Medical Radiology—Radiation Therapy Physics 1995 Springer-Verlag Berlin 365 384
10. Robert B Mach J-P Mani J-C Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor Cancer Res 56 1996 4758 4765
11. Stickney DR Anderson LD Slater JB Bifunctional antibody: A binary radiopharmaceutical delivery system for imaging colorectal carcinoma Cancer Res 51 1991 6650 6655
12. Rouvier E Gautherot E Meyer P Targeting medullary thyroid carcinomas with bispecific antibodies and bivalent haptens: Results and clinical perspectives Horm Res 47 1997 163 167
13. 111In-labeled hapten to bifunctional antibody in human colon, tumor xenografts Cancer Res 51 1991 1515 1520
14. Reardan DT Meares CF Goodwin DA Antibodies against metal chelates Nature 316 1985 265 268
15. Meyer DL Fineman M Unger BW Kinetics of the dissociation of indium-(para-substituted-benzyl)ethylenediaminetetraacetic acid hapten analogs from the monoclonal anti-hapten antibody CHA255 Bioconjugate Chem 1 1990 278 284
16. Yuan F Baxter LT Jain RK Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies Cancer Res 51 1991 3119 3130
17. Mattes MJ On the validity of “functional affinity” determination for antibodies binding to cell surface antigens or other polyvalent antigens Cancer Res 55 23 suppl 1995 5733s 5735s
18. (suppl) Goodwin DA Meares CF Pretargeting—general principles Cancer 80 1997 2675 2680
19. Goodwin DA Meares CF McTigue M Pretargeted immunoscintigraphy: Effect of hapten valency on murine tumor uptake J Nucl Med 33 1992 2006 2013
20. Chinol M Paganelli G Sudati F Biodistribution in tumour-bearing mice of two Y-90-labelled biotins using three-step tumour targeting Nucl Med Commun 18 1997 176 182
21. Application: WO 94-US14174941207. Priority: US 93-163188 931207, US Patent Theodose LJ Meyer DL Mallett RW Pretargeting methods and compounds for pretargeted delivery of diagnostic and therapeutic agents PCT Int Appl, CODEN: PIXXD2. WO9515979 AI 950615 1993
22. [published erratum appears in Proc Natl Acad Sci. U S A 1996;93(18):9991 George AJ Jamar F Tai MS Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: Technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide Proc Natl Acad Sci U S A 92 1995 8358 8362
23. Nicholson S Gooden CSR Hird V Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: A matched analysis Oncol Rep 5 1998 223 226
24. DeNardo SJ Kukis DL Kroger LA Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: Efficacy and toxicity in breast cancer xenografts Proc Natl Acad Sci U S A 94 1997 4000 4004
25. Sundberg MW Meares CF Goodwin DA Chelating agents for the binding of metal ions to macromolecules Nature 250 1974 587 588
26. Yeh SM Sherman DG Meares CF A new route to “bifunctional” chelating agents: Conversion of amino acids to analogs of ethylenedinitrilotetraacetic acid Analyt Biochem 100 1979 152 159
27. Moi MK Meares CF McCall MJ Copper chelates as probes of biological systems: Stable copper complexes with a macrocyclic bifunctional chelating agent Analyt Biochem 148 1985 249 253
28. Moi MK Meares CF DeNardo SJ The peptide way to macrocyclic bifunctional chelating agents: Synthesis of 2-(p-Nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,-N′,N″,N″' -tetraacetic acid and study of its yttrium (III) complex J Am Chem Soc 110 1988 6266 6267
29. Li M Meares CF Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates Bioconjugate Chem 4 1993 275 283
30. (suppl) Langer R Drug delivery and targeting Nature 392 1998 5 10
31. Flessner MF Dedrick RL Tissue-level transport mechanisms of intraperitoneally-administered monoclonal antibodies J Controlled Release 53 1998 69 75
32. Taylor-Papadimitriou J Epenetos AA Exploiting altered glycosylation patterns in cancer: Progress and challenges in diagnosis and therapy Trends Biotechnol 12 1994 227 233
33. Rose LM Gunasekera AH Denardo SJ Lymphoma selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10 Cancer Immunol Immunother 43 1996 26 30
34. Nicholson S Gooden CSR Hird V Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: A matched analysis Oncol Rep 5 1998 223 226
35. DeNardo SJ Kukis DL Miers LA Yttrium-90-DOTA-peptide chimeric L6 radioimmunoconjugate: Efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts J Nucl Med 39 1998 842 849
36. DeNardo GL Kukis DL Shen S Efficacy and toxicity of 67-Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt's lymphoma (Raji) Clin Cancer Res 3 1997 71 79
37. Knox S, Meredith R: Radioimmunotherapy, In Tepper J, Gunderson L (eds): Clinical Radiation Oncology, London, Churchill Livingston, (in press)
38. Siegel JA Thomas SR Stubbs JB MIRD Pamphlet No. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates J Nucl Med 40 1999 37s 61s
39. Mausner LF Srivastava SC Selection of radionuclides for radioimmunotherapy Med Phys 20 1993 503 509
40. Huneke RD Pippin CG Squire RA Effective alphaparticle-mediated radioimmunotherapy of murine leukemia Cancer Res 52 1992 5819 5820
41. Order SE Vriesendorp HM Klein JL A phase I study of 90-yttrium antiferritin: Dose escalation and tumor dose Antib Immunoconj Radiopharmaceut 1 1988 163 168
42. Gray BN Burton MA Kelleher D Tolerance of the liver to the effects of yttrium-90 radiation Int J Radiat Oncol Biol Phys 18 1990 619 623
43. Yorke ED Beaumier PL Wessels BW Optimal antibody-radionuclide combinations for clinical radioimmunotherapy: A predictive model based on mouse pharmacokinetics Nucl Med Biol 18 1991 827 835
44. Howell RW Goddu SM Rao DV Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy Med Phys 25 1998 37 42
45. Maxon HR Englaro EE Thomas SR Radioiodine-131 therapy for well-differentiated thyroid cancer—a, quantitative radiation dosimetric approach: Outcome and validation in 85 patients J Nucl Med 33 1992 1132 1136
46. Press OW Treatment of recurrent lymphomas with unmodified antibodies and radioimmunoconjugates Tumor Targeting 1 1995 31 35
47. Kaminski MS Zasadny KR Francis IR Iodine-131-antiB1 radioimmunotherapy for B-cell lymphoma J Clin Oncol 14 1996 1974 1981
48. Porter AT McEwan AJB Strontium 89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: Results of a randomized controlled trial Semin Oncol 20 suppl 2 1993 38 43
49. Pentlow KS Graham MC Lambrecht RM Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy Med Phys 18 1991 357 366
50. Breitz HB Fisher DR Weiden PL Dosimetry of rhenium-186-labeled monoclonal antibodies: Methods, prediction from technetium-99m-labeled antibodies, and results of phase I trials J Nucl Med 34 1993 908 917
51. Leichner PK Koral KF Jaszczak RJ An overview of imaging techniques and physical aspects of treatment planning for radioimmunotherapy Med Phys 20 1993 569 577
52. Glaser V Processing Mabs Companies pursue range of strategies for monoclonal therapeutics Genetic Engineering News 18 1998 1 55
53. Thayer AM Great expectations: Biopharmaceutical industry expects success from new drug therapies, and a full product development pipeline Chem Eng News 76 1998 19
54. Loevinger R Japha EM Brownell GL Discrete radioisotope sources Hime GJ Brownell GL Radiation Dosimetry 1956 Academic New York, NY 693 799
55. Berger MJ Distribution of absorbed doses around point sources of electrons and beta particles in water and other media. MIRD pamphlet 7 J Nucl Med 12 suppl 5 1971 1 23
56. Lederer CM Hollander JM Perlman J Table of isotopes ed 6 1968 Wiley New York, NY